Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 15, 2022 | Series C | €22M | 9 | Pureos Bioventures Trill Impact | — | Detail |
Dec 15, 2022 | Debt Financing | €50M | 1 | European Investment Bank | — | Detail |
Dec 15, 2020 | Series B | €47.40M | 7 | Wellington Partners | — | Detail |
Sep 8, 2020 | Series Unknown | — | 1 | — | — | Detail |
Jan 21, 2019 | Grant | €4.40M | 3 | Novo Holdings Repair Impact Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Pureos Bioventures | Yes | Series C |
Trill Impact | Yes | Series C |
European Investment Bank | Yes | Debt Financing |
Novo Holdings | Yes | Grant |
Adjuvant Capital | — | Series C |
Industrifonden | — | Series C |
LF Investment | — | Series C |
Repair Impact Fund | — | Series C |
Sanofi Ventures | — | Series C |
Sunstone Life Science Ventures | — | Series C |